Correspondence 0001193125-24-266104 from Coya Therapeutics, Inc. (COYA)
Coya Therapeutics, Inc.
Date: Nov. 26, 2024 · CIK: 0001835022 · Accession: 0001193125-24-266104
AI Filing Summary & Sentiment
File numbers found in text: 333-283366
Show Raw Text
CORRESP 1 filename1.htm CORRESP November 26, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Coya Therapeutics, Inc. (the “Company”) Registration Statement on Form S-3 (File No. 333-283366) Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 4:00 p.m., Eastern Time, on November 29, 2024, or as soon as practicable thereafter. Please call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 to confirm the effectiveness of the Registration Statement or with any questions. Very truly yours, COYA THERAPEUTICS, INC. By: /s/ Arun Swaminathan Name: Arun Swaminathan Title: Chief Executive Officer (Principal Executive Officer)